PubMed
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GH-releasing hormone analog
Teichman et al., 2006
GH SecretagoguesResearch OnlyD
CJC-1295 (no DAC)
Modified GRF 1-29
Short-acting CJC/GRF variant used for pulse-style GH protocols.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- D
- Experience
- 56
- Activity
- 42
Overall check-ins
Trackers & reports
Overview
About CJC-1295 (no DAC)
Short-acting CJC/GRF variant used for pulse-style GH protocols.
- Category
- GH Secretagogues
- Regulatory status
- Research Only
- Also known as
- Modified GRF 1-29
- Self-reports
- 81
Community
What 81 users report
81 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 98% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Sleep
203
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
198
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.05–2 mg
0.05–0.1 mg
12
0.1–0.2 mg
64
0.2–0.4 mg
117
0.4–0.6 mg
5
1–2 mg
5
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 68 days · Based on 32 repeat reporters
Research
Cited research (3)
Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo et al., 2008
PubMed
Advances in the detection of growth hormone releasing hormone synthetic analogs
Memdouh et al., 2021
Tools
Explore more
Explore
More ways to learn about CJC-1295 (no DAC) from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about CJC-1295 (no DAC)?
This page summarizes 81 anonymized self-reports from PeptIQ users who track CJC-1295 (no DAC), including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for CJC-1295 (no DAC)?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for CJC-1295 (no DAC)?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is CJC-1295 (no DAC) safe to use?
This wiki does not assess safety or recommend use. CJC-1295 (no DAC) is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of CJC-1295 (no DAC)?
This wiki summarizes observational community reports and linked citations for CJC-1295 (no DAC). It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for CJC-1295 (no DAC) for study-level context — not medical advice.
What is the legal status of CJC-1295 (no DAC)?
CJC-1295 (no DAC) is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of CJC-1295 (no DAC)?
Safety data quality for CJC-1295 (no DAC) varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on CJC-1295 (no DAC)?
This page links 3 indexed sources for CJC-1295 (no DAC). Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.